BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 36682020)

  • 1. Predicting PD-L1 expression status in patients with non-small cell lung cancer using [
    Zhao X; Zhao Y; Zhang J; Zhang Z; Liu L; Zhao X
    EJNMMI Res; 2023 Jan; 13(1):4. PubMed ID: 36682020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer.
    Zhou J; Zou S; Kuang D; Yan J; Zhao J; Zhu X
    Front Oncol; 2021; 11():769272. PubMed ID: 34868999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Construction of A Nomogram Prediction Model for PD-L1 Expression 
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
    Hao L; Wang L; Zhang M; Yan J; Zhang F
    Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
    Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
    J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features.
    Wen Q; Yang Z; Dai H; Feng A; Li Q
    Front Oncol; 2021; 11():620246. PubMed ID: 34422625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by
    Li J; Ge S; Sang S; Hu C; Deng S
    Front Oncol; 2021; 11():789014. PubMed ID: 34976829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep learning radiomics model based on PET/CT predicts PD-L1 expression in non-small cell lung cancer.
    Li B; Su J; Liu K; Hu C
    Eur J Radiol Open; 2024 Jun; 12():100549. PubMed ID: 38304572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An [
    Meng N; Feng P; Yu X; Wu Y; Fu F; Li Z; Luo Y; Tan H; Yuan J; Yang Y; Wang Z; Wang M
    Eur Radiol; 2024 Jan; 34(1):318-329. PubMed ID: 37530809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of pre-therapy
    Zhang J; Zhao X; Zhao Y; Zhang J; Zhang Z; Wang J; Wang Y; Dai M; Han J
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1137-1146. PubMed ID: 31728587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([
    Hughes DJ; Josephides E; O'Shea R; Manickavasagar T; Horst C; Hunter S; Tanière P; Nonaka D; Van Hemelrijck M; Spicer J; Goh V; Bille A; Karapanagiotou E; Cook GJR
    Eur Radiol; 2024 Feb; ():. PubMed ID: 38388716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Machine learning based on clinico-biological features integrated
    Ren C; Zhang J; Qi M; Zhang J; Zhang Y; Song S; Sun Y; Cheng J
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1538-1549. PubMed ID: 33057772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive Assessment of HER2 Expression Status in Gastric Cancer Using
    Jiang X; Li T; Wang J; Zhang Z; Chen X; Zhang J; Zhao X
    Cancer Biother Radiopharm; 2024 Apr; 39(3):169-177. PubMed ID: 38193811
    [No Abstract]   [Full Text] [Related]  

  • 13. [
    Yang M; Li X; Cai C; Liu C; Ma M; Qu W; Zhong S; Zheng E; Zhu H; Jin F; Shi H
    Eur Radiol; 2023 Dec; ():. PubMed ID: 38127071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a
    Liu H; Cui Y; Chang C; Zhou Z; Zhang Y; Ma C; Yin Y; Wang R
    BMC Cancer; 2024 Jan; 24(1):150. PubMed ID: 38291351
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Hu S; Kang Y; Xie Y; Yang T; Yang Y; Jiao J; Zou Q; Zhang H; Zhang Y
    Abdom Radiol (NY); 2023 Feb; 48(2):532-542. PubMed ID: 36370179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT.
    Monaco L; De Bernardi E; Bono F; Cortinovis D; Crivellaro C; Elisei F; L'Imperio V; Landoni C; Mathoux G; Musarra M; Pagni F; Turolla EA; Messa C; Guerra L
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3401-3411. PubMed ID: 35403860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiomics of
    Mu W; Tunali I; Gray JE; Qi J; Schabath MB; Gillies RJ
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1168-1182. PubMed ID: 31807885
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Liu F; Xiang Z; Li Q; Fang X; Zhou J; Yang X; Lin H; Yang Q
    Clin Radiol; 2024 Jan; 79(1):e147-e155. PubMed ID: 37884401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naïve patients with non-small cell lung cancer.
    Zhang R; Hohenforst-Schmidt W; Steppert C; Sziklavari Z; Schmidkonz C; Atzinger A; Kuwert T; Klink T; Sterlacci W; Hartmann A; Vieth M; Förster S
    Nuklearmedizin; 2022 Oct; 61(5):385-393. PubMed ID: 35768005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study.
    Tong H; Sun J; Fang J; Zhang M; Liu H; Xia R; Zhou W; Liu K; Chen X
    Front Immunol; 2022; 13():859323. PubMed ID: 35572597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.